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Drug resistance is the major obstacle in successfully treating high-risk neuroblastoma. The aim of this 
study was to investigate the basis of etoposide-resistance in neuroblastoma. To this end, a MYCN-
amplified neuroblastoma cell line (HTLA-230) was treated with increasing etoposide concentrations and 
an etoposide-resistant cell line (HTLA-ER) was obtained. HTLA-ER cells, following etoposide exposure, 
evaded apoptosis by altering Bax/Bcl2 ratio. While both cell populations shared a homozygous TP53 
mutation encoding a partially-functioning protein, a mono-allelic deletion of 13q14.3 locus, where 
the P53 inducible miRNAs 15a/16-1 are located, and the consequent miRNA down-regulation were 
detected only in HTLA-ER cells. This event correlated with BMI-1 oncoprotein up-regulation which 
caused a decrease in p16 tumor suppressor content and a metabolic adaptation of HTLA-ER cells. These 
results, taken collectively, highlight the role of miRNAs 15a/16-1 as markers of chemoresistance.
Neuroblastoma (NB) is one of the most common extra-cranial solid tumors in childhood and it is character-
ized by high clinical and biological heterogeneity1,2. Among the genetic changes most frequently associated with 
the aggressive cancer phenotype, the amplification of the MYCN proto-oncogene is an important predictor of 
high-risk NB3. Although most high-risk NB patients initially respond to therapy, a majority of these patients will 
relapse with treatment-resistant disease. It has been found that approximately 50% of relapsed NBs are associated 
with the inactivation of the TP53 tumor-suppressor gene pathways4.
The loss of function of the P53 protein may derive either from the mutations of the TP53 gene5, the interaction 
of P53 with its endogenous inhibitor MDM26, or from the transcriptional and/or post-transcriptional regulation 
of P53 and P53-dependent genes7.
In NB, TP53 mutations are rare at diagnosis8 but P53 inactivation occurs relatively often (~50%) following 
therapeutic treatment9. However, the molecular mechanisms leading to P53 impairment in treatment-resistant 
diseases have not yet been elucidated. In this context, we have recently demonstrated that HTLA-230, a 
MYCN-amplified human NB cell line chronically treated with the clinically-used drug etoposide10, developed 
etoposide-resistance and also acquired a multi-drug resistance (MDR) phenotype, thus becoming able to effi-
ciently repair DNA damage and evade apoptosis11. Since apoptotic failure, a critical hallmark of cancer12, is often 
determined by the loss of the tumor suppressor activity of P53, herein we initiated the investigation of the role of 
the P53 pathway in the acquisition of the MDR phenotype.
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In recent years, a key role in the acquisition of chemoresistance has been attributed specifically to micro-RNAs 
(miRNAs13,14), which are a family of small non-coding RNAs that have been demonstrated to regulate multiple 
mechanisms such as drug efflux, drug metabolism, DNA methylation and repair and apoptosis15.
In NB, miRNAs have been identified to be down- or up-regulated and associated with MYCN amplification 
and chemoresistance13,16. Interestingly, several miRNAs are able to modulate P53 expression and P53 itself is able 
to regulate the expression of several miRNAs17. Therefore, in the present study, our attention was extended to the 
involvement of the P53-miRNA network in the observed chemoresistance.
Results
Acute etoposide treatment does not modify the mitotic index or the Bax/Bcl2 ratio of HTLA-ER 
cells. We have recently demonstrated that acute etoposide exposure induced DNA damage, apoptosis and a 
decrease in the proliferation rate in HTLA-230 cells but not in the etoposide-resistant ones11. The decrease in the 
proliferation rate of HTLA-230 cells after acute etoposide treatment was confirmed by mitotic index analysis. As 
shown in Fig. 1A, etoposide reduced the mitotic index of HTLA parental cells by 87% while the same treatment 
did not significantly affect the replicative ability of etoposide-resistant cells (HTLA-ER).
Considering the different effects induced by etoposide on the two cell populations, we hypothesized that 
the acquisition of resistance could be due to changes in the expression of pro- and anti-apoptotic proteins. 
Immunoblot analysis showed that, following etoposide exposure, Bax levels were increased by 25% in HTLA 
parental cells and decreased by 35% in HTLA-ER in comparison with the untreated cells (Fig. 1B, upper and left 
lower panel and Fig. 1 supplementary).
In addition, a significant reduction in the Bcl2 level was observed in etoposide-treated HTLA parental cells 
in respect to HTLA-ER cells whose Bcl2 level was in fact enhanced after etoposide exposure (Fig. 1B, upper and 
left lower panel and Fig. 1 supplementary). The expression levels of the pro-apoptotic PUMA protein (α and β 
isoforms), known to interact with Bcl2-family members, were also analyzed and were found unchanged under 
any of the treatment conditions (Fig. 2 supplementary). In conclusion, the marked increase of Bax/Bcl2 ratio in 
etoposide-treated parental cells (Fig. 1B, right panel) could explain their propensity to undergo apoptosis in con-
trast with etoposide-treated HTLA-ER cells.
HTLA-ER and parental cells have a common homozygous TP53 missense mutation, not 
responsible per se for the acquisition of chemoresistance. Since P53 protein plays a key role in the 
cellular response to genotoxic stress, as well as in the induction and repression of Bax and Bcl-2 respectively4,18, 
its modulation, following etoposide treatment, was investigated in both cell lines. Firstly, gene array analyses 
revealed that the TP53 mRNA was overexpressed 7.5 fold in HTLA-ER cells in respect to parental ones (Fig. 3 
supplementary). However, immunoblot analysis showed that the two cell populations had a similar high amount 
of P53 protein which was not inducible by etoposide treatment (Fig. 2A and Fig. 1 supplementary). Moreover, 
also the level of MDM2 protein, the endogenous inhibitor of P53, was similar and not modified by etoposide 
treatment in both cell populations (Fig. 4A supplementary), in agreement with the lack of MDM2 amplification 
revealed by cytogenetic analysis (Fig. 4B supplementary).
The presence of the high amount of P53 protein prompted us to investigate the status of the TP53 locus. 
Functional Analysis of Separated Alleles in Yeast (FASAY)19 and DNA sequencing (see Materials and Methods) 
revealed that both cell lines carried a single homozygous TP53 missense mutation at codon 161 that causes the 
substitution of Alanine with Threonine (GCC > ACC, A161T).
The functional characterization of the identified TP53 mutation showed that the P53 A161T is 
temperature-sensitive since, when analyzed with a quantitative yeast functional assay20–22, it retained a high 
transactivation ability at 30 °C but not at 36 °C (Fig. 2B). Such heterogeneity in transactivation was not due to 
temperature-dependent differences in protein steady-state levels (Fig. 5A supplementary and Fig. 6A supplemen-
tary). When expressed in HCT116 (TP53−/−) mammalian cells, the P53 A161T mutant confirmed the yeast-based 
data (Fig. 2C, Fig. 5B supplementary and Fig. 6B supplementary).
Therefore, since the same mutation was found in both cell populations, the acquisition of chemoresistance of 
HTLA-ER is not due to the appearance of a TP53 mutation in these cells.
Acute etoposide treatment induced P53 Ser15 phosphorylation in HTLA-230 cells but not in 
HTLA-ER cells. Considering that P53 is phosphorylated on Ser15 following DNA damage23, the phospho-
rylation status of this site was investigated. As shown in Fig. 3A and Fig. 1 supplementary, etoposide treatment 
markedly stimulated P53 Ser15 phosphorylation only in the parental cells. Given that the status of Ser15 phos-
phorylation is regulated by several phosphatases and kinases, their role was taken into consideration. In this con-
text, a two-fold increase in the expression of PPM1D/Wip1, the major phosphatase involved in this process24, was 
found in both untreated and etoposide-treated HTLA-ER cells in respect to the parental cells (Fig. 3B). Moreover, 
etoposide treatment reduced the expression of PPM1D in HTLA-230 cells by 50% while no significant changes 
were observed in ER cells (Fig. 3B).
The potential contribution of kinases involved in the P53 pathway, namely ATM, ATR and CHK125, was 
firstly investigated by microarray analysis that showed a similar expression of the three kinases in parental and in 
HTLA-ER cell lines (Fig. 3 supplementary). These results are in agreement with the cytogenetic analysis revealing 
that both cell lines showed nuclei with a single signal at 11q22.3 ATM locus (Fig. 3C). As CHK1 locus maps onto 
11q24.2, we can suppose that also this locus was present in a single copy. Moreover, both cell lines showed two 
chromosomes 17 displaying 17p13 TP53 locus indicating also that no TP53 deletion was present (Fig. 3C).
Therefore, we can hypothesize that the different status of P53 Ser15 phosphorylation in parental and resistant 
cells is due to the differences in the PPM1D phosphatase expression and not to an altered expression of the three 
main kinases involved in this regulation.
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HTLA-ER cells have a monoallelic deletion at 13q14.3 locus which is accompanied by reduced 
levels of miRNAs 15a/16-1. It has been reported that, in response to stress conditions, P53 induces the 
expression of several miRNAs including miRNA-34a26 and the miRNA-15a/miRNA-16-1 cluster, the latter being 
able to reduce the level of Bcl2 and trigger cell death27.
To better investigate the effect of the difference in P53 Ser15 phoshorylation found in HTLA-230 and 
HTLA-ER cells on P53-miRNA network, the involvement of miRNA-34a and miRNA-15a/miRNA-16-1 was 
analyzed.
MiRNA-34a was reduced in both cell populations after etoposide exposure in comparison with untreated ones 
(Fig. 4B). Considering that a balanced translocation t(1;17)(p36;q21) involving the 1p36 microdeletion region 
where miRNA-34a maps has already been demonstrated in HTLA-230 parental cells28, the integrity of 1p36 chro-
mosomal region was investigated also in HTLA-ER cells. Our FISH analysis with a probe for 1p36 region revealed 
Figure 1. The mitotic index of HTLA-ER cells and their Bax/Bcl2 ratio were not modified by acute etoposide 
exposure. (A) Mitotic index of HTLA-230 and HTLA-ER cells untreated or treated for 24 hrs with 1.25 μM 
etoposide. Histograms summarize quantitative data of means ± S.D. of four independent experiments 
per experimental condition (at least 4 × 103 cells per experimental condition were counted) **p < 0.01 vs. 
untreated HTLA-230 cells. (B) Protein levels of Bax and Bcl2 in HTLA-230 and HTLA-ER cells untreated or 
treated for 24 hrs with 1.25 μM etoposide. Immunoblots are representative of three independent experiments 
with essentially similar results. β-Actin is the internal loading control. The histograms on the left summarize 
quantitative data of protein level means, normalized to β-actin expression ± S.E.M of three independent 
experiments. The histograms on the right summarize quantitative data of Bax/Bcl2 ratio means ± S.E.M of three 
independent experiments. *p < 0.05 vs. untreated HTLA-230 cells; **p < 0.01 vs. untreated HTLA-230 cells; 
§§p < 0.01 vs. untreated HTLA-ER cells.
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the presence of the same chromosome 1 rearrangement in both cell populations (Fig. 4A) confirming that the 
described t(1;17)(p36;q21) translocation, present in both cell populations, was indeed not associated with a loss of 
the 1p36 region. Moreover, at least 43% of HTLA-ER cells also showed a duplication of the 1p derivative bearing 
the 1p36 region (Fig. 4A right panel), indicating the presence of two different subclones.
Similarly, the involvement of miRNAs 15a/16-1 was analyzed by checking the integrity of the chromosomal 
region 13q14.3 where they are located. The deletion of this region is reported in several malignancies and it has 
been associated with a loss of tumor suppressor function29. As reported in Fig. 5A, interphase FISH analysis 
showed the presence of two 13q14.3 and 13q34 (used as control marker) loci in the nuclei of parental cells, while 
it revealed only one 13q14.3 locus and three 13q34 loci in HTLA-ER cells. Moreover, metaphase FISH analysis 
showed two normal chromosomes 13, each containing 13q14.3 and 13q34 loci, in HTLA-230 cells and one nor-
mal and one rearranged chromosome 13, carrying a del(13q14.3) and a dup(13q34), in HTLA-ER cells (Fig. 5A).
In agreement with the observed deletion at the 13q14.3 locus, untreated HTLA-ER cells were characterized by 
a 70% (Fig. 5B, left panel) and 100% (Fig. 5B, right panel) reduction of miRNA-15a and of miRNA-16-1 expres-
sion, respectively, in comparison to untreated parental cells. Moreover, while in parental cells the expression of 
miRNA-15a and miRNA-16-1 were increased following etoposide treatment by 100% and 44%, respectively, in 
HTLA-ER cells, the expression level of miRNA-15a and miRNA-16-1 remained unchanged (Fig. 5B). Since both 
cell lines contained a partially active P53 mutant, the regulation of miRNAs in HTLA-230 cells can be considered 
P53 independent. In conclusion, these results clearly indicate that HTLA-ER cells have a monoallelic deletion at 
Figure 2. Parental and HTLA-ER cells express a non-inducible P53 protein carrying the homozygous TP53 
missense mutation A161T. (A) Protein levels of P53 in HTLA-230 and HTLA-ER cells untreated or treated 
for 24 hrs with 1.25 μM etoposide. Immunoblots are representative of three independent experiments with 
essentially similar results. β-Actin is the internal loading control. (B) Transactivation ability of wild-type and 
mutant (A161T) P53 proteins in yLFM-P21-5′, yLFM-BAX A + B and yLFM-MDM2P2C yeast strains. The 
transactivation ability was determined at two different temperatures (30 °C and 36 °C) using a constitutive 
expression of P53 proteins (ADH1 promoter). Presented data are the fold of induction over empty vector 
(pRS315) and standard deviation of four biological replicates. #p < 0.001 vs. wild-type P53. (C) Transactivation 
ability of wild-type and mutant (A161T) P53 proteins on reporter constructs (P21, BAX and MDM2) in 
HCT116 TP53−/− human cells. Renilla luciferase was used to normalize transfection efficiencies. Data are 
expressed as fold of induction relative to the results obtained with an empty vector (pCIneo). Presented data are 
the average and standard deviations of three biological replicates. #p < 0.001 vs. wild-type P53.
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Figure 3. P53 Ser15 phosphorylation is detected only in etoposide-treated HTLA parental cells and is 
associated with PPM1D up-regulation. (A) Protein levels of phospho-(Ser15)-P53 in HTLA-230 and 
HTLA-ER cells untreated or treated for 24 hrs with 1.25 μM etoposide. Immunoblots are representative of three 
independent experiments with essentially similar results. β-Actin is the internal loading control. Histograms 
summarize quantitative data of phospho-P53/P53 ratio means ± S.E.M of three independent experiments. 
**p < 0.01 vs. untreated HTLA cells. (B) RT-PCR analysis of PPM1D/Wip1 in HTLA-230 and HTLA-ER cells 
untreated or treated for 24 hrs with 1.25 μM etoposide. Histograms summarize quantitative data of PPM1D 
normalized with means ± S.E.M of three independent experiments. *p < 0.05 vs. untreated HTLA cells; 
**p < 0.01 vs. untreated HTLA cells; °°p < 0.01 vs. 1.25 µM etoposide-treated HTLA cells. (C) FISH analysis of 
HTLA-230 and HTLA-ER cells: upper panels) nuclei of HTLA-230 and HTLA-ER cells with two TP53 and one 
ATM signals; lower panels) metaphase FISH analysis of HTLA-230 and HTLA-ER cells with two chromosomes 
17 displaying one TP53 signal each and one chromosome 11 displaying ATM signal.
www.nature.com/scientificreports/
6SCIENtIFIC REPORTS |  (2018) 8:13762  | DOI:10.1038/s41598-018-32195-7
the 13q14.3 locus, which is accompanied by reduced levels of miRNAs 15a/16-1 that remained unchanged after 
etoposide treatment.
Reduced levels of miRNA-15a and miRNA-16-1 in HTLA-ER cells correlate with the increased 
expression of BMI-1. The reduced expression of miRNA-15a and miRNA-16-1, as well as the lack of their 
induction following etoposide treatment, can only be partially responsible for the increase in Bcl2 levels found 
in HTLA-ER cells. In fact, both untreated HTLA-230 and HTLA-ER cells have comparable Bcl2 levels (Fig. 1B) 
while the level of miRNAs 15a/16-1 was significantly lower in HTLA-ER than in HTLA-230 cells, regardless of 
etoposide treatment (Fig. 5B).
BMI-1 protein (B lymphoma Mo-MLV insertion region 1), which is a direct target of miRNA-15a and 
miRNA-16-130, has been reported to be essential for the tumorigenicity of neuroblastoma cells31 and to mediate 
the up-regulation of Bcl232. In accordance, microarray analysis revealed that the expression of BMI-1 increased 
5-fold in HTLA-ER in respect to parental cells (Fig. 3 supplementary). Moreover, the BMI-1 overexpression was 
directly related to the higher levels (+80%) of BMI-1 protein in both untreated and etoposide-treated HTLA-ER 
in respect to parental cells (Fig. 6A and Fig. 1 supplementary). However, no changes in BMI-1 following etoposide 
treatment were observed in both cell lines, indicating a Bcl2 modulation not strictly dependent on BMI-1.
Lastly, as BMI-1 is able to regulate cell proliferation33 also by down regulating p1634, the levels of this tumor 
suppressor was analyzed. As reported in Fig. 6B and Fig. 1 supplementary, p16 levels were reduced by 35% in 
HTLA-ER in respect to parental cells. In addition, p16 content was increased by 45% in parental cells follow-
ing etoposide treatment while it remained unchanged in HTLA-ER cells (Fig. 6B and Fig. 1 supplementary). 
Altogether, the data pointed out the down-regulation of miRNA-15a and miRNA-16-1 as the major trigger of 
HTLA-ER chemoresistance by enhancing the basal level of BMI-1 expression, with important consequences on 
downstream targets (e.g. p16).
Figure 4. 1p36 allelic loss is not observed in parental and HTLA-ER cells and miRNA-34a levels are reduced 
in both cell populations following etoposide treatment. (A) FISH analysis of HTLA-230 cells and HTLA-ER 
cells. Upper and lower left panels: metaphase of both HTLA-230 and HTLA-ER cells displays one normal 
chromosome 1 (close arrow) one 1 p arm derivative (close arrowhead) and 1 q arm derivative (open arrow); 
lower right panel: metaphase of HTLA-ER cells displaying one additional 1 p arm derivative (open arrowhead). 
(B) Expression levels of miRNA-34a in HTLA-230 and HTLA-ER cells untreated or treated for 24 hrs 
with 1.25 μM etoposide. Histograms summarize quantitative data of means ± S.E.M of three independent 
experiments. **p < 0.01 vs. untreated HTLA-ER cells.
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Discussion
Chemotherapy plays a crucial role in the treatment of cancer but its clinical success is often limited by the acqui-
sition of a therapy-induced resistance35. In this regard, we have recently demonstrated that long-term exposure to 
etoposide, a common clinically-used chemotherapeutic drug, is able to select a population of drug-resistant NB 
cells (HTLA-ER cells) since they are unable to undergo apoptosis11.
In this article, we show that drug-sensitive HTLA-230 cells respond to etoposide treatment by decreasing their 
replicative activity while HTLA-ER cells do not significantly change the mitotic index of untreated cells (Fig. 1). 
Taking these different cellular responses into account, we have hypothesized that the resistant phenotype of 
Figure 5. HTLA-ER cells have a deletion at the 13q14.3 locus which is associated with decreased levels of 
miRNAs 15a/16-1 in respect to parental cells. (A) FISH analysis of HTLA-230 and HTLA-ER cells: Upper 
panels: nuclei of HTLA-230 cells with two CEP12, two 13q34 and two D13S319 signals; nuclei of HTLA-ER cells 
with two CEP12, three 13q34 and one D13S319 signals. Lower panels: metaphase of HTLA-230 cells with two 
chromosomes 13 displaying 13q34 and D13S319 signals; metaphase of HTLA-ER cells with one chromosome 
13 displaying 13q34 and D13S319 signals, one rearranged chromosome 13 displaying two 13q34, and one 
chromosome 12 displaying cep 12signal. (B) Expression levels of miRNA-15a (left panel) and miRNA-16 (right 
panel) in HTLA-230 and HTLA-ER cells untreated or treated for 24 hrs with 1.25 μM etoposide. Histograms 
summarize quantitative data of means ± S.E.M of three independent experiments. **p < 0.01 vs. untreated 
HTLA-230 cells.
www.nature.com/scientificreports/
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HTLA-ER cells might be the consequence of a different balance between the expression of pro- and anti-apoptotic 
proteins.
In agreement with literature, demonstrating that an imbalance of the Bax/Bcl2 ratio in favor of Bcl2 contrib-
utes to rendering cancer cells more resistant to apoptosis36, HTLA-ER cells, after short-term etoposide exposure, 
show an increased amount of Bcl2 that efficiently counteracts the pro-apoptotic function of BAX and/or PUMA 
(Figs 1 and 2 supplementary)37 becoming unable to undergo apoptosis (Fig. 7).
Focusing our attention on P53, a critical modulator of Bcl2 family members4,18, we have found that: (i) TP53 
mRNA overexpression in HTLA-ER cells is not accompanied by an increase in the protein level (Figs 2 and 
3 supplementary); (ii) the amount of P53 protein is high and not inducible in either cell line (Fig. 2); and (iii) 
MDM2, the primary negative regulator of P53 (Fig. 4 supplementary)38, is not amplified in either cell population. 
Moreover, our results show that HTLA-230 and HTLA-ER cells have a homozygous TP53 mutation (A161T) 
which encodes for a P53 protein with partial transactivation activity (Figs 2 and 5 supplementary).
Since the acquisition of chemoresistance in HTLA-ER cells is not due to the alterations of the TP53 gene, we 
hypothesized that post-translational modifications, important for P53 activation, might play a crucial role. In this 
regard, we have found that P53 phosphorylation on Ser15, which is crucial for the activation of P53-dependent 
responses39, is absent in etoposide-treated ER cells (Figs 3 and 7). This event can be correlated to the overex-
pression of PPM1D/Wip1 (Figs 3 and 7), a key phosphatase able to modulate the P53 phosphorylated status24. 
Interestingly, it has been demonstrated that the high expression of PPM1D is the most likely target of the 
17q23gain/amplification in NB and is related to a poor clinical outcome40.
The P53-miRNAs network is an important player in regulating chemoresistance41 and the miRNA-34a expres-
sion is induced by P5342. In this context, the 1p36 locus, where miRNA-34a maps, has not been found deleted in 
either parental or resistant cells in spite of the presence of the balanced t(1;17)(p36;q21) translocation described 
in HTLA-230 cells28. This leads us to exclude the role of miRNA-34a in the acquisition of chemoresistance 
in HTLA-ER cells. We then focused our attention on miRNA-15a/16-1 which are other important players of 
chemoresistance and are induced by P53. MiRNAs 15a/16-1 are located on the 13q14.3 locus, and miRNA-16-1 
regulates PPM1D expression43, leading us to hypothesize a potential role of these miRNAs in the drug-resistance 
of HTLA-ER cells.
In this direction, we have found that the genetic feature that distinguishes HTLA-ER from parental cells con-
sists of the monoallelic deletion of the 13q14.3 locus in which miRNA-15a and miRNA-16-1 are located (Figs 5 
and 7)29. It is worth noting that the 13q14.3 locus has frequently been found deleted in tumors29,44 but our results 
demonstrate for the first time that the deletion is present in etoposide-resistant NB cells. In accordance with data 
from other authors, the down-regulation of miRNA-15a and miRNA-16-1 induces an enhancement of the TP53 
mRNA27,45, not associated with a proportional increase of the P53 protein.
It is important to note that in our model the reduced expression of miRNA-15a/16-1 in HTLA-ER cells was 
not correlated with Bcl2 levels since a Bcl-2 increase was observed in ER cells only after acute etoposide exposure. 
Therefore, it is possible to hypothesize that other mechanisms are responsible for the up-regulation of Bcl2 fol-
lowing etoposide treatment.
In addition, it has been reported that miRNA-15a and miRNA-16-1 directly modulate the expression of 
BMI-1 protein which is highly expressed in several kinds of tumors with a poor prognosis30,31,46. In this regard, 
Figure 6. BMI-1 overexpression with consequent p16 down-regulation is found in HTLA-ER cells in respect 
to parental cells. (A) Protein levels of BMI-1 in HTLA-230 and HTLA-ER cells untreated or treated for 24 hrs 
with 1.25 μM etoposide. Immunoblots are representative of three independent experiments with essentially 
similar results. β-Actin is the internal loading control. Histograms summarize quantitative data of protein 
expression levels means, normalized to β-actin expression ± S.E.M of three independent experiments. *p < 0.05 
vs. untreated HTLA-230 cells; °p < 0.05 vs. 1.25 µM etoposide-treated HTLA-230 cells. (B) Protein levels of 
p16 in HTLA-230 and HTLA-ER cells untreated or treated for 24 hrs with 1.25 μM etoposide. Immunoblots are 
representative of three independent experiments with essentially similar results. β-Actin is the internal loading 
control. Histograms summarize quantitative data of protein expression levels means, normalized to β-actin 
expression ± S.E.M of three independent experiments. *p < 0.05 vs. untreated HTLA-230 cells.
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we show that the low level of miRNAs 15a/16-1 in HTLA-ER cells leads to BMI-1 induction which in turn 
reduces the expression of the tumor-suppressor protein p16 (Figs 6 and 7)33,47, thus contributing to HTLA-ER 
chemoresistance.
In our in vitro model of etoposide-resistance, we have previously demonstrated that HTLA-ER cells are char-
acterized by higher levels of glutathione (GSH) and an up-regulation of catalase and superoxide dismutase activ-
ity in respect to parental cells: this antioxidant response leads to a lower production of reactive oxygen species 
(ROS)11.
Interestingly, in chemoresistant ovarian cancer cells, it has been demonstrated that BMI-1 expression regulates 
GSH production42. Thus, the high level of BMI-1 in HTLA-ER cells could enhance the GSH content and hamper 
the pro-oxidant action of the drug, reducing its cytotoxicity (Fig. 7). The intracellular redox state might well con-
tribute to the inhibition of etoposide-induced γ-H2AX expression and P53 Ser15 phosphorylation in HTLA-ER 
cells (Fig. 7). The increased level of GSH in the resistant NB cells is probably also due to the stimulation of an 
efficient aerobic metabolism11. These findings are consistent with other studies demonstrating that agents deplet-
ing GSH, in combination with conventional therapeutics, synergistically improve the efficacy of the treatment of 
neuroblastoma11,48. Lastly, it is also worth noting that, as reported in many drug-resistant cancers49, HTLA-ER 
cells have an increased activity of glutathione S-transferase (GST), which is a phase II detoxification enzyme, 
catalyzing the conjugation of GSH with electrophilic substrates. In particular, we have previously reported that 
both GST expression and activity were increased about 2 fold in etoposide treated resistant cells11. Here, we found 
that 43% of HTLA-ER cells showed a duplication of 1p arm (Fig. 4A, right panel), which is known to include the 
locus of glutatione S-transferase M1, an enzyme belonging to the GST family50. Therefore, we can hypothesize 
that also the duplication of the 1p arm might contribute to the observed chemoresistant phenotype of NB cells.
Summarizing, our results show that chronic treatment with etoposide of a high-risk NB cell line correlated 
with a monoallelic deletion of the 13q14.3 locus and a marked down-regulation of miRNA-15a/16-1 levels. This 
leads to the up-regulation of BMI-1 protein with pleiotropic effects such as the activation of GSH-dependent 
responses which could be involved in the metabolic adaptation of drug resistant NB cells (Fig. 7).
However, further studies are needed to highlight the potential role of these miRNAs as markers of drug resist-
ance and also as therapeutic targets in order to modulate the epigenetic changes supporting NB chemoresistance.
Figure 7. Molecular mechanisms underlying the chemoresistance of HTLA-ER cells. This figure illustrates 
the observed molecular mechanisms underlying chemoresistance of HTLA-ER cells and the events leading 
to apoptosis in etoposide sensitive HTLA parental cells. Left panel: Short-term treatment with etoposide of 
HTLA-230 cells reduces oxidative phosphorylation and decreases glutathione (GSH) levels inducing reactive 
oxygen species (ROS) overproduction, thus leading to DNA damage (H2AX). Consequently, etoposide-
induced genotoxic stress increases pro-apoptotic Bax, reduces anti-apoptotic Bcl2 and stimulates P53-Ser15 
phosphorylation, two events leading to apoptosis and chemosensitivity. Right panel: HTLA-ER cells are able 
to efficiently counteract etoposide-induced ROS production by maintaining an efficient aerobic metabolism 
and increasing GSH levels. Long-term treatment with etoposide causes a deletion of the 13q14.3 locus and the 
consequent downregulation of miRNAs 15a/16-1, stimulating several pro-survival signals which contribute to 
inducing chemoresistance.
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Materials and Methods
Cell cultures. NB cell culture conditions and treatments. The MYCN-amplified human stage-IV NB cell 
line, HTLA-230, was obtained from Dr. L. Raffaghello (G. Gaslini Institute, Genoa, Italy). Cytogenetic features of 
HTLA-230 cell line including 4p MYCN amplification, del(11)t(11;Y), balanced translocation t(1;17)(p36;q21) 
and dup(11p) have been previously described by Pezzolo et al.28. The cell line was periodically tested for myco-
plasma contamination (Mycoplasma Reagent Set, Aurogene s.p.a, Pavia, Italy). After thawing and eight passages 
in the culture, cell morphology and proliferation were analyzed. Cells were cultured in RPMI 1640 (Euroclone 
SpA, Pavia, Italy) supplemented with 10% fetal bovine serum (FBS; Euroclone), 2 mM glutamine (Euroclone), 1% 
penicillin/streptomycin (Euroclone), 1% sodium pyruvate (Sigma-Aldrich, Sant Louis, Missouri, USA), and 1% 
of aminoacid solution (Sigma).
The etoposide-resistant cell line (HTLA-ER) was selected by treating HTLA-230 cells for 6 months with 
increasing concentrations of etoposide11.
Parental HTLA-230 and HTLA-ER cells were treated for 24 hrs with 1.25 µM etoposide (Calbiochem, Merck 
KGaA, Darmstadt, Germany). The stock solutions of etoposide were prepared in DMSO and pilot experiments 
demonstrated that the final DMSO concentrations did not change any of the cell responses analyzed.
Yeast cell culture conditions. S. Cerevisiae yeast cells were grown in YPDA medium (1% yeast extract, 2% 
peptone, 2% dextrose, 200 mg/L adenine) or in a selective medium containing dextrose as a carbon source 
and adenine (5 mg/L or 200 mg/L) but lacking leucine or tryptophan for the selection of the expression vector 
(Sigma-Aldrich; BiokarDiagnostics, Allonne, France). All transformations of yeast cells were based on a lithium 
acetate method51.
Human colon carcinoma cell culture conditions. HCT116 TP53−/− cells (human colon carcinoma) were obtained 
by Dr. B. Vogelstein (The Johns Hopkins Kimmel Cancer Center, Baltimore, MD). Cells were grown in RPMI 
containing 10% fetal bovine serum (Euroclone) and maintained at 37 °C in 5% CO2 at 100% humidity.
Mitotic Index. Exponentially-growing HTLA-230 and HTLA-ER cells were seeded 24 hrs before drug treat-
ment on 8-well chamber slides (Thermo Fisher Scientific, Waltham, MA USA) or on 24 × 24 coverslips. After 
24 hrs of treatment, cells were fixed in methanol:glacial acetic acid 3:1 for 15 min at 4 °C. After fixation, cells were 
washed in PBS and counterstained with DAPI for 5 min or with 3% Giemsa Stain for 15 min. Finally, cells were 
observed using an epifluorescence microscope (Provis AX70, Olympus, Milano, Italy); mitoses and interphases 
(at least 500 cells per experimental condition) were counted from two independent scores in four independent 
experiments.
Immunoblot analysis. Immunoblot analysis of NB cell protein extracts. NB cell protein extract was pre-
pared as previously described52. Immunoblots were carried out according to standard methods53 using rab-
bit antibodies anti-bax and anti-bcl2 (Abcam, Cambridge, UK), anti-PUMA and anti-BMI1 (Cell Signalling 
Technology Inc., Danvers, MA, USA), a phospho-p53 Antibody Sampler Kit (Cell Signaling Technology Inc.) 
and mouse antibodies anti-β-actin (Sigma), anti-MDM2 and anti-p16 (Santa Cruz Biotechnology Inc., Dallas, 
Texas, USA). Anti-mouse and anti-rabbit secondary antibodies were coupled with horseradish peroxidase 
(GeHealthcare, Buckinghamshire, UK). Proteins were visualized with an enzyme-linked chemiluminescence 
detection kit according to the manufacturer’s (GeHealthcare) instructions. Chemiluminescence was monitored 
by exposure to film and the signals were analyzed under non-saturating conditions with an image densitometer 
connected to Quantity One software (Bio-Rad Laboratories, Hercules, CA, USA).
Immunoblot analysis of yeast and mammalian protein extracts from reporter assays. Yeast extracts were prepared 
as described54. Briefly, yeast cells recovered from plates were resuspended in 100 μl of distilled water and 100 μl 
of 0.2 M NaOH. After 5 min of incubation at room temperature, the cells were pelleted, resuspended in 50 μl SDS 
sample buffer (0.06 M TrisHCl, pH 6.8, 5% glycerol, 2% SDS, 4% β-mercaptoethanol, 0.0025% bromophenol 
blue), boiled for 3 min and pelleted again.
Twenty μl of yeast supernatant and 20 μg of mammalian cell extracts in Passive Lysis Buffer (PLB, Promega, 
Madison, Wisconsin, U.S.A) from transformation and transfection assays, respectively were loaded on 12% 
SDS-PAGE using a Biorad MiniProtean apparatus (Bio-Rad) and transferred to a nitrocellulose membrane 
(GEHealthcare). Detection was carried out with ECL Fast Pico (ECL-1002, Immunological Sciences, Roma, Italy). 
Chemiluminescence was analyzed by Alliance LD, UVITEC Cambridge (Cambridge, UK).
The following antibodies were employed: anti-p53 (DO-1, sc-126, Santa-Cruz), anti-β-actin (AC-74, Sigma), 
anti-yeast Phosphoglycerate Kinase 1 (PGK1)(22C5D8, Thermo Fisher Scientific) and a secondary anti-mouse 
IgG peroxidase conjugate (A9044, Sigma).
Cytogenetic analysis. Interphase nuclei and metaphase preparation. Interphase nuclei were obtained by 
detaching cells with trypsin EDTA. C-metaphases were obtained by standard procedures, using 0.1 μg/mL colce-
mid (GIBCO BRL, Thermo Fisher Scientific) for 2 hrs. All samples were then fixed in methanol:glacial acetic acid 
3:1, splashed, dried, and aged 2–3 days before hybridization procedures.
Fluorescence In Situ Hybridization (FISH) analysis. Cytogenetic abnormalities were determined by FISH 
analysis. Amplification of the MDM2 gene was investigated by using the LSI MDM2/CEP12 FISH probe kit 
(Abbott-Vysis, Roma, Italy) which included the SpectrumOrange-labeled LSI MDM2 probe that hybridizes 
the 12q15 locus containing the MDM2 gene and the SpectrumGreen CEP 12 probe that hybridizes the alphoid 
sequences found within the centromere of chromosome 12 (12p11.1-q11). The following abnormalities including 
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del13q14 (D13S319 probe), del11q22 (ATM probe), del17p13 (TP53 probe) and trisomy 12 (CEP 12 DNA 
Probe) were tested by using a disease-specific comprehensive probe set (Abbott-Vysis). This probe set included: 
(i) the SpectrumGreen-labeled LSI ATM probe (732 kb in size) that hybridizes the 11q22.3 locus containing 
RAB39, CUL5 and EXPH5 genes other than the ATM gene (ii) the SpectrumOrange-labeled LSI TP53 probe, 
that hybridizes the 17p13.1 locus containing the complete TP53 gene (iii) the SpectrumOrange-labeled LSI 
D13S319 probe which is 135 kb in length and hybridizes the 13q14.3 locus encompassing the DLEU1 locus and 
(iv) the SpectrumAqua-labeled LSI 13q34 that hybridizes the 13q34 locus used as control. The 1p deletion was 
investigated using the 1p36 Microdeletion Region Probe (Abbott-Vysis). This probe included (i) LSI p58 (1p36) 
(SpectrumOrange) (ii) TelVysio 1p (SpectrumGreen) used as control and (iii) LSI 1q25 (SpectrumAqua) used as 
control. Standard interphase FISH was performed according to the manufacturers’ recommendations. At least 
200 nuclei were analyzed for each probe by two independent scores. Metaphases were also analyzed.
Digital image analysis. Images were acquired using an epifluorescence microscope (as above) equipped 
with a digital monochrome progressive CCD camera (CV-M4 + CL progressive scan, JAI Corporation, Japan) 
driven by CytoVision™ system (Applied Imaging, SAN JOSE, CA, USA). DAPI, FITC, TRITC and AQUA images 
were acquired with selective single-bandpass filters at 100x optical magnification, and merged.
Gene expression analysis by cDNA microarray. The expression of 18,401 human genes was tested by 
cDNA microarray. Custom microarrays, made available by the Microarray Department-University of Amsterdam, 
were used55,56. The whole list of spotted genes is available on the website http://www.micro-array.nl/libraries.html. 
All data is MIAME-compliant as detailed on the MGED Society website (http://www.mged.org/Workgroups/
MIAME/miame.html). Microarrays were made available by the Microarray Department of the University of 
Amsterdam (http://www.micro-array.nl). The gene expression analysis was performed, as previously reported11. 
The call/response rate obtained was >90%, which was used as quality criterion for microarray analysis.
RNA extraction and reverse transcription. Total RNA was extracted using TRIZOL reagent 
(LifeTechnologies, Carlsbad, California, USA) according to the manufacturer’s instructions. Total RNA (1 μg) 
was reverse-transcribed into cDNA by a random hexamer primer and SuperScript™ II Reverse Transcriptase 
(LifeTechnologies).
Functional Analysis of Separated Alleles in Yeast (FASAY). The FASAY assay is used to define the 
functional status (wild-type or mutant) of a TP53 allele. This assay exploits the yIG397 S. Cerevisiae yeast strain 
that contains the ADE2 open reading frame under the control of a p53-responsive element (3XRGC); the ADE2 
gene is involved in the biosynthetic pathway of adenine. Cells containing wild-type P53 express ADE2 and form 
white colonies on the plate with a limited amount of adenine (5 mg/L). Conversely, cells containing a mutant P53 
(i.e. not able to transactivate the reporter gene) do not express ADE2 and generate small red colonies on the same 
plates due to an accumulation of a colored intermediate product in the biosynthetic pathway of adenine19.
To perform this analysis, cDNA from HTLA-230 and HTLA-ER cells was firstly amplified by using TP53 
specific primers P3 and P419 and Exact Polymerase (5 Prime). The following PCR conditions were used: 1 min 
of denaturation at 94 °C, 1 min of annealing at 55 °C and 1 min of elongation at 72 °C (30 cycles). An initial 
heat-activation step at 95 °C for 5 min was required. The yIG397 yeast strain was then co-transformed with unpu-
rified P53 PCR product (10 µl) and pRDI22 HindIII/StuI digested vector (50 ng). In the yeast, the plasmid is 
re-sealed together with the PCR products by recombination, exploiting the sequence homology at the end of the 
fragments (Gap Repair Assay)19. By analyzing the TP53 status from a cell line, it is expected that the presence of a 
non-functional TP53 allele in heterozygosity generates around 50% of small red colonies. In the case of homozy-
gosity for the presence of a non-functional TP53 allele, the yeast cells are expected to be all red. The background 
level of the assay was also evaluated by using PCR amplification (P3-P4) on the pLS76 plasmid template that 
harbours the wild-type TP53 cDNA.
The output of the described analysis showed a percentage of red yeast colonies over the total number of trans-
formants (white and red colonies) of 16.9% and 14.2% for parental and HTLA-ER cells, respectively, suggesting 
the presence of a functional (wild-type) P53 protein (referred at 30 °C).
Sequencing of TP53 PCR product. PCR on TP53 cDNA was performed with primers P1 and P10 
(Table 1) that span the entire TP53 coding sequence. The previously described PCR conditions were used. 
The purified PCR product (QIAquick PCR purification Kit, Qiagen, Hilden, Germany) was sequenced 
with primers P5 and P6 (Table 2; BMR Genomics, Padua, Italy). In order to accurately check the sequence, 
including the 15–20 N-terminal and C-terminal amino acidic residues (i.e. residues that cannot be analyzed 
Official Gene Symbol Primers
TP 53 (P1) 5′-atggaggagccgcagtcagatcctagcgtc-3′
TP 53 (P5) 5′-tggccatctacaagcagtca-3′
TP 53 (P6) 5′-gggcaccaccacactatgtc-3′
TP 53 (P10) 5′-tcagtctgagtcaggcccttctgtcttgaa-3′
PPM1D Forward 5′-atttcgctgggcggattttg-3′Reverse 5′-agtggagcttcgcatagagc-3′
Table 1. Sequence of primers used for PCR analyses.
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for technical reason by the previous analysis), we decided to clone the cDNA of parental HTLA-230 and 
HTLA-ER cells in a yeast expression vector (pTS-based, TRP1 as selection marker). To this end, the TP53 
cDNA sequence was amplified using a pair of primers that are characterized by a 5′ homology (in bold) 
with the XhoI/NotI double digested pTS-based vector and by a 3′ homology with TP53 cDNA (underlined): 
Nter: 5′- caagctataccaagcatacaatcaactatctcatatacagttaactcgagatggaggagccgcagtcagatcctagcgtc-3′; Cter: 
5′-gacataactaattacatgatggtggcggccgctctagaactagtggatcctcagtctgagtcaggcccttctgtcttgaa-3′. The pTS vector har-
boring the cDNA of parental HTLA-230 or HTLA-ER cells was constructed using the previously described Gap 
Repair Assay (see above). Plasmid DNA was recovered from yeast colonies, expanded in E. coli, and checked by 
digestion. At least two different clones, deriving from PCR amplification of cDNA from parental HTLA-230 or 
HTLA-ER cells, were verified by DNA sequencing (P5 and P6 primers) (BMR Genomics).
Construction of mutant TP53 allele by a two-step PCR mutagenic approach. A pair of comple-
mentary 30-mer oligonucleotides (which served as forward and reverse primers) was synthesized with the mutated 
base adjacent to the central position of the oligonucleotide (A161T forward: 5′-gtccgcgccatgaccatctacaagcagtca-3′; 
A161T reverse: 5′-tgactgcttgtagatggtcatggcgcggac-3′)20. The forward and reverse primers were used in two sepa-
rate PCR reactions (for conditions see above) and paired with P4 and P3 primers respectively, using pLS76 plas-
mid as a template. As previously described, homologous recombination in vivo in yeast was exploited by using 
the two PCR products and the pRDI22 HindIII/StuI digested vector. The re-sealed plasmid DNA was recovered 
from yeast transformants through genomic extraction and expanded in E. coli. The presence of the specific TP53 
mutation (GCC > ACC, A161T) was verified at the molecular level by DNA sequencing (BMR Genomics).
Yeast functional reporter assay. The yLFM-P21-5′, yLFM-BAX A + B and yLFM-MDM2P2C strains 
were used to quantitatively evaluate the functionality of the P53 mutant (A161T); all strains are isogenic except 
for the different Response Element (RE) located upstream from the luciferase reporter gene57. Briefly, yeast strains 
were transformed with pLS-based expression vectors (encoding wild-type and mutant P53 from the ADH1 con-
stitutive promoter) along with the empty vector pRS315.
The functional assay was carried out according to the miniaturized protocol previously developed by us21. 
Yeast transformants (selected on 200 mg/L adenine plates) were grown at two different temperatures (30 °C and 
37 °C) and then resuspended in 150 μl of water. OD (600 nm) was directly measured in a transparent 96-well plate. 
The cell suspension (20 μl) was transferred into a white plate and mixed with an equal volume of PLB buffer 2X 
in order to obtain the lysis of yeast cells. After 15 min of shaking at room temperature, firefly luciferase substrate 
(20 μl, Bright Glo, Promega) was added. Luciferase activity was measured using a multilabel plate reader (Mithras 
LB940, Berthold Technologies) and normalized to OD 600 nm. The transactivation ability of the wild-type and 
mutant P53 proteins was expressed as fold of induction over empty vector (pRS315).
Mammalian functional reporter assay. Wild-type and mutant (A161T) P53 proteins were expressed by 
a pCIneo-based vector. The mutant P53 expression vector was first constructed in a yeast pTSG-based plasmid 
(through SgraI/StuI digestion and subsequent ligation) from the available yeast pLS-based vector. The mam-
malian pCI-neo plasmid was then obtained from XhoI/NotI double digestion of the pTSG-based vector along 
with the empty pCI-neo backbone. The presence of the correct sequence was confirmed by sequencing (BMR 
Genomics).
HCT116 TP53−/− cells were seeded in 24-well plates (8 × 105 cells) and transfected using the TransIT-LT1 
transfection reagent (Mirus, Milan, Italy) according to the manufacturer’s instructions. The transfection mix-
ture (500 ng/well) contained 250 ng of the different pGL3 promoter-derived p53 reporter plasmids, 200 ng of 
the expression or empty vector, and 50 ng of the pRL-SV40 control plasmid. Cells were harvested 24 hrs after the 
transfection, washed with PBS and lysed for 15 min with PLB 1X. Luciferase assays were conducted as previously 
described58.
Real time PCR analysis. Validation of microarray data was performed by real time-qPCR for PPMD1 gene 
(Table 1) SYBRGREEN fluorescent tracer was used to identify amplicons whose identity was checked by melting 
curve analysis. Primer sequences (TIB Molbiol, Italy) were identified according to http://www.ncbi.nlm.nih.gov/
tools/primer-blast/database. cDNAs were prepared using Superscript II Reverse Transcription kit (Invitrogen, 
Milan, Italy). PCR was performed in a Rotor-Gene 3000 Corbett Research, Mortlake, Australia). Each reaction 
was carried out using 10xPCR buffer, 100 mM dNTPs mix, 50 mM MgCl2, 10 µM primer F, 10 µM primer R, 5 U/μl 
Platinum® Taq DNA polymerase (Invitrogen), cDNA (diluted 1:10), and SYBRGREEN® (Invitrogen) in a 50-μl 
reaction volume. The thermal profile consisted of hot-start enzyme activation at 95 °C for 2 min, 45 cycles of PCR 
at 94 °C for 45 sec (denaturation), at 62 °C for 30 sec (gene-specific temperature annealing) and at 72 °C for 30 sec 
(elongation). Gene expression was normalized to the GAPDH housekeeping gene.
Universal Reverse 
Primer Sequence of probes TaqMan assay I
has-miR-16-1 5′- uagcagcacguaaauauuggcg -3′ 4427975AssaYID 000391
has-miR-15a 5′- uagcagcacaucaugguuuaca- 3′ 4427975AssayID000390
has-miR-34a 5′-caaucagcaaguauacugcccu-3′ 4427975 AssayID002316
RNU38B 5′- TCTCAgTgATgAAAACTTTgTCCAg-3′ 4427975ASSAYID 01004
Table 2. Sequences of primers and probes used for TaqMan qPCR.
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miRNA expression analysis. Total RNA (10 ng) was reverse transcribed using miR-specific stem-loop RT 
primers (TaqMan MicroRNA Assays; Applied Biosystems, Thermo-Fisher) and components of the High Capacity 
cDNA Reverse Transcription kit (Life Technologies) according to the manufacturer’s protocols. Expression 
levels of individual miRNAs were detected by subsequent RQ-PCR using TaqMan MicroRNA assays (Life 
Technologies) and a Rotor Gene 3000 PCR System Corbett (Qiagen) using standard thermal cycling conditions in 
accordance with manufacturer recommendations. PCR reactions were performed in triplicate in final volumes of 
30 µl, including inter-assay controls (IAC) to account for variations between runs. RT-PCR (TaqMan MicroRNA 
Assays; Applied Biosystems, Thermo-Fisher) was used to quantify the expression of has-miR-16-1, has-miR-15a 
and of has-miR-34a according to the manufacturer’s instructions (Table 2). To normalize the data for quantifying 
miRNAs, the universal small nuclear RNU38B (RNU38B Assay ID 001004; Applied Biosystems) as an endoge-
nous control was used (Table 2)59.
The delta–delta Ct method was employed to calculate the fold change. In brief, each 15 μl of the reaction sys-
tem contained 0.15 μl of 100 mM dNTPs with dTTP, 1 μl of MultiScribe Reverse Transcriptase (50 U/μl), 1.5 μL 
of RT buffer (×10), 0.1 μl of RNase inhibitor (20 U/μl), 6.25 μl of nuclease-free water, 5 μl of small RNA, and 3 μl 
of RT primer. Small RNAs are quantified by Qubit 3 fluorimeter (Life Technology). Thermal-cycling conditions 
were 30 min at 16 °C, 30 min at 42 °C, and 5 min at 85 °C. Each 20 μl of the reaction system for real-time quantita-
tive PCR contained 1 μl of real-time primer, 1.33 μl of product from RT reaction, 10 μl of TaqMan Universal PCR 
Master Mix, and 7.67 μl of nuclease-free water. The reactions were performed in triplicate on a Rotor Gene 3000 
PCR System Corbett for 10 min at 95 °C, followed by 40 cycles of 15 s at 95 °C and 1 min at 60 °C. Along with the 
Cq-values calculated automatically by the SDS software (threshold value = 0.2, baseline setting: cycles 3–15), raw 
fluorescence data (Rn-values) were exported for further analyses.
Statistical analysis. Results were expressed as mean ± SEM from at least three independent experi-
ments. The statistical significance of parametric differences among the sets of experimental data was evaluated 
by one-way ANOVA and Dunnett’s test for multiple comparisons. Statistical analysis of the mitotic index and 
reporter assays data was performed using the Fisher’s exact test.
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